Page 53 - Toksoplazmoz Tanı ve Tedavi Uzlaşı Raporu

Toksoplazmoz Tanı ve Tedavi Uzlaşı Raporu

36. Antinori A, Ammassari A, de Luca A, Cingolani A, Murri R, Scoppettuolo 50. Chirgwin K, Hafner R, Leport C, Remington J, Andersen J, Bosler EM, et
G, et al. Diagnosis of AIDS-related focal brain lesions: A decision-making al. Randomized phase II trial of atovaquone with pyrimethamine or
analysis based on clinical and neuroradiologic characteristics combined sulfadiazine for treatment of toxoplasmic encephalitis in patients with
with polymerase chain reaction assays in CSF. Neurol 1997;48:687-94. acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS
https://doi.org/10.1212/WNL.48.3.687 Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Es-
sai 039. Clin Infect Dis 2002;34:1243-50. https://doi.org/10.1086/339551
37. Cinque P, Scarpellini P, Vago L, Linde A, Lazzarin A. Diagnosis of central
nervous system complications in HIV-infected patients: cerebrospinal 51. Kovacs JA, The NIAID-Clinical Center Intramural AIDS Program. Efficacy
fluid analysis by the polymerase chain reaction. AIDS (London, England) of atovaquone in treatment of toxoplasmosis in patients with AIDS. The
1997;11:1-17. https://doi.org/10.1097/00002030-199701000-00003 NIAID-Clinical Center Intramural AIDS Program. Lancet (London, Eng-
land) 1992;340:637-8. https://doi.org/10.1016/0140-6736(92)92172-C
38. Nogui FL, Mattas S, Turcato Júnior G, Lewi DS. Neurotoxoplasmosis
diagnosis for HIV-1 patients by real-time PCR of cerebrospinal fluid. 52. Department of Health and Human Services. Notice of availability of
Braz J Infect Dis. 2009 Feb;13(1):18-23. https://doi.org/10.1590/S1413- pyrimethamine. Available on: https://aidsinfo.nih.gov/news/1604/no-
86702009000100006 tice-of-availability-of-pyrimethamine (Erişim tarihi: 16.09.2015).
39. Mesquita RT, Ziegler ÂP, Hiramoto RM, Vidal JE, Pereira-Chioccola VL. 53. Deen JL, von Seidlein L, Pinder M, Walraven GE, Greenwood BM. The safe-
Real-time quantitative PCR in cerebral toxoplasmosis diagnosis of Bra- ty of the combination artesunate and pyrimethamine-sulfadoxine given
zilian human immunodeficiency virus-infected patients. J Med Microbiol during pregnancy. Trans R Soc Trop Med Hyg 2001;95(4):424-8. https://
2010;59(Pt 6):641-7. https://doi.org/10.1099/jmm.0.016261-0 doi.org/10.1016/S0035-9203(01)90204-4
40. Katlama C, De Wit S, O’Doherty E, Van Glabeke M, Clumeck N. Pyrimeth- 54. Bachmeyer C, Mouchnino G, Thulliez P, Blum L. Congenital toxoplas-
amine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long- mosis from an HIV-infected woman as a result of reactivation. J Infect
term therapy for toxoplasmic encephalitis in patients with AIDS. Clin 2006;52. https://doi.org/10.1016/j.jinf.2005.05.004
Infect Dis 1996;22(2):268-75. https://doi.org/10.1093/clinids/22.2.268 55. Lago EG, Conrado GS, Piccoli CS, Carvalho RL, Bender AL. Toxoplasma
gondii antibody profile in HIV-infected pregnant women and the risk of
41. Dannemann B, McCutchan JA, Israelski D, Antoniskis D, Leport C, Luft B, congenital toxoplasmosis. Eur J Clin Microbiol Infect Dis 2009;28:345-51.
et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A ran- https://doi.org/10.1007/s10096-008-0631-2
domized trial comparing pyrimethamine plus clindamycin to pyrimeth-
amine plus sulfadiazine. The California Collaborative Treatment Group. 56. Low incidence of congenital toxoplasmosis in children born to women
Ann Intern Med 1992;116(1):33-43. https://doi.org/10.7326/0003-4819- infected with human immunodeficiency virus. European Collaborative
116-1-33 Study and Research Network on Congenital Toxoplasmosis. Eur J Obstet
Gynecol Reprod Biol 1996;68(1-2):93-6. https://doi.org/10.1016/0301-
42. Nath A, Sinai AP. Cerebral Toxoplasmosis. Curr Treat Options Neurol 2003 2115(96)02497-9
Jan;5(1):3-12. https://doi.org/10.1007/s11940-003-0018-8
57. Minkoff H, Remington JS, Holman S, Ramirez R, Goodwin S, Landesman
43. Jordan MK, Burstein AH, Rock-Kress D, Alfaro RM, Pau AK, Kovacs JA, et S. Vertical transmission of toxoplasma by human immunodeficiency
al. Plasma pharmacokinetics of sulfadiazine administered twice daily virus-infected women. AJOG 1997;176:555-9. https://doi.org/10.1016/
versus four times daily are similar in human immunodeficiency virus-in- S0002-9378(97)70547-7
fected patients. Antimicrob Agents Chemother 2004;48(2):635-7. https://
doi.org/10.1128/AAC.48.2.635-637.2004 58. Duval X, Pajot O, le Moing V, Longuet P, Ecobichon JL, Mentre F, et al.
Maintenance therapy with cotrimoxazole for toxoplasmic encephalitis
44. Torre D, Casari S, Speranza F, Donisi A, Gregis G, Poggio A, et al. Ran- in the era of highly active antiretroviral therapy. AIDS (London, England)
domized trial of trimethoprim-sulfamethoxazole versus pyrimeth- 2004;18:1342-4. https://doi.org/10.1097/00002030-200406180-00016
amine-sulfadiazine for therapy of toxoplasmic encephalitis in patients
with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chem- 59. Katlama C, Mouthon B, Gourdon D, et al. Atovaquone as long-term sup-
pressive therapy for toxoplasmic encephalitis in patients with AIDS and
other 1998;42(6):1346-9. https://doi.org/10.1128/AAC.42.6.1346
multiple drug intolerance. Atovaquone Expanded Access Group. AIDS
45. Béraud G, Pierre-François S, Foltzer A, Abel S, Liautaud B, Smadja D, 1996;10:1107.
Cabié A. Cotrimoxazole for treatment of cerebral toxoplasmosis: an 60. Lejeune M, Miró JM, De Lazzari E, García F, Claramonte X, Martínez E, e
observational cohort study during 1994-2006. Am J Trop Med Hyg al. Restoration of T cell responses to Toxoplasma gondii after successful
2009;80(4):583-7. https://doi.org/10.4269/ajtmh.2009.80.583
combined antiretroviral therapy in patients with AIDS with previous
46. Hernandez A v., Thota P, Pellegrino D, Pasupuleti V, Benites-Zapata VA, toxoplasmic encephalitis. Clin Infect Dis 2011;52(5):662-70. https://doi.
Deshpande A, et al. A systematic review and meta-analysis of the rela- org/10.1093/cid/ciq197
tive efficacy and safety of treatment regimens for HIV-associated cere- 61. Furco A, Carmagnat M, Chevret S, Garin YJF, Pavie J, de Castro N, et al.
bral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option? HIV Restoration of Toxoplasma gondii-specific immune responses in patients
Medicine 2017;18:115-24. https://doi.org/10.1111/hiv.12402 with AIDS starting HAART. AIDS (London, England) 2008;22:2087-96.
47. Dedicoat M, Livesley N. Management of toxoplasmic encephalitis in https://doi.org/10.1097/QAD.0b013e3283136d68
HIV-infected adults (with an emphasis on resource-poor settings). 62. Guex AC, Radziwill AJ, Bucher HC. Discontinuation of secondary proph-
The Cochrane Database of Systematic Reviews 2006. https://doi. ylaxis for toxoplasmic encephalitis in human immunodeficiency virus
org/10.1002/14651858.CD005420.pub2 infection after immune restoration with highly active antiretroviral ther-
48. Jacobson JM, Hafner R, Remington J, Farthing C, Holden-Wiltse J, Bos- apy. Clin Infect Dis 2000;30(3):602-3. https://doi.org/10.1086/313733
ler EM, et al. Dose-escalation, phase I/II study of azithromycin and py- 63. Soriano V, Dona C, Rodríguez-Rosado R, Barreiro P, González-Lahoz J.
rimethamine for the treatment of toxoplasmic encephalitis in AIDS. AIDS Discontinuation of secondary prophylaxis for opportunistic infections in
(London, England) 2001;15:583-9. https://doi.org/10.1097/00002030- HIV-infected patients receiving highly active antiretroviral therapy. AIDS
200103300-00007 (London, England) 2000;14:383-6. https://doi.org/10.1097/00002030-
49. Torres RA, Weinberg W, Stansell J, Leoung G, Kovacs J, Rogers M, et al. 200003100-00011
Atovaquone for salvage treatment and suppression of toxoplasmic en- 64. Zeller V, Truffot C, Agher R, Bossi P, Tubiana R, Caumes E, et al. Discontin-
cephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis uation of secondary prophylaxis against disseminated Mycobacterium
Study Group. Clin Infect Dis 1997;24:422-9. https://doi.org/10.1093/clin- avium complex infection and toxoplasmic encephalitis. Clin Infect Dis
ids/24.3.422 2002;34(5):662-7. https://doi.org/10.1086/338816

44